Back to Top Skip to main content

DoD Pharmacy & Therapeutics Committee

The Department of Defense Pharmacy & Therapeutics (DoD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. 

To learn more, please see the Dec 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified 22 Mar 2005).

DoD P&T Committee Meeting Schedule

View DoD P&T Meeting Minutes See Archived Meeting Pages


February 7-8, 2018

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: November 3, 2017
  • Pre-Proposal Teleconference: November 9, 2017 @ 1200 Central 
  • Clinical/Cost Presentation Meeting Window: November - December, 2017
  • UF BPA & UF ADP Quotes Due: January 5, 2018 
  • P&T Committee Meeting: February 7-8, 2018
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • Anti-inflammatory Immunomodulatory Ophthalmic Agents - Opthalmic Immunomodulatory Agents: 
    • Restasis
    • Restasis Multidose
    • Xiidra
  • Diabetes Non-Insulin - Glucagon-like Peptide-1 (GLP-1) Receptor Agonists:
    • Adlyxin
    • Byetta
    • Trulicity
    • Victoza
  • Osteoporosis Agents - PTH Analogues: 
    • Forteo
    • Tymlos
  • Corticosteroids-Immune Modulators - Adrenocorticotropic Hormomes:
    • H.P. Acthar

November 15-16, 2017

Uniform Formulary Request for Quote Information
  • UF BPA & UF ADP RFQ Documents Posted: August 21, 2017
  • Pre-Proposal Teleconference: September 7, 2017 @ 1200 Central 
  • Clinical/Cost Presentation Meeting Window: August - September, 2017
  • UF BPA & UF ADP Quotes Due: October 13, 2017 
  • P&T Committee Meeting: November 15-16, 2017
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • Weight Loss Agents: Belviq, Belviq XR, Contrave, Qsymia, Saxenda, Xenical
  • Oncological Agents - Multiple Myeloma: Alkeran, Farydak, Melphalan, Ninlaro, Pomalyst, Revlimid, Thalomid
  • Prenatal Vitamins
  • ArmonAir RespiClick
  • Baxdela
  • Benlysta
  • Bevyxxa
  • Cotempla XR ODT
  • Duzallo
  • Endari
  • Fiasp
  • Flolipid
  • Fycompa O/S
  • Gocovri
  • Haegarda
  • Idhifa
  • Mavyret
  • Nerlynx
  • Nityr
  • Symproic
  • Trelegy Ellipta
  • Tremfya
  • Verzenio
  • Vosevi

August 9-10, 2017

Uniform Formulary Request for Quote Information
  • UF BPA & UF ADP RFQ Documents Posted: May 5, 2017
  • Pre-Proposal Teleconference: May 18, 2017 @ 1200 Central 
  • Clinical/Cost Presentation Meeting Window: May - June, 2017
  • UF BPA & UF ADP Quotes Due: June 30, 2017 
  • P&T Committee Meeting: August 9-10, 2017
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • Antiretrovirals - Combinations: Atripla, Complera, Genvoya, Odefsey, Stribild, Triumeq
  • Antiretrovirals - Integrase Strand Transfer Inhibitors (INSTIs): Isentress, Tivicay, Vitekta
  • Antiretrovirals - Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTIs): Descovy, Emtriva, Trizivir, Truvada, Viread, Ziagen
  • Antiretrovirals - Other Agents: Aptivus, Crixivan, Edurant, Evotaz, Intelence, Invirase, Kaletra, Lexiva, Norvir, Prezcobix, Prezista, Rescriptor, Selzentry, Tybost, Viracept
  • Corticosteroids/Immune Modulators - Hereditary Angioedema Agents: Berinert, Cinryze, Firazyr, Kalbitor, Ruconest
  • Insulins - Basal: Basaglar Kwikpen U-100, Lantus, Lantus Solostar, Levemir, Levemir Flexpen, Levemir Flextouch, Toujeo Solostar, Tresiba Flextouch U-100, Tresiba Flextouch U-200
  • AirDuo RespiClick
  • Alunbrig
  • Ingrezza
  • Intrarosa
  • Jadenu Sprinkle
  • Kevzara
  • Kisqali Femara Co-Pack
  • Morphabond ER
  • Mydayis ER
  • Rydapt
  • Siliq
  • Syndros
  • Tymlos
  • Xadago
  • Xatmep
  • Zejula

May 10-11, 2017

Uniform Formulary Request for Quote Information
  • UF BPA & UF ADP RFQ Documents Posted: February 15, 2017
  • Pre-Proposal Teleconference: February 21, 2017 @ 1400 Central 
  • Clinical/Cost Presentation Meeting Window: March - April, 2017
  • UF BPA & UF ADP Quotes Due: April 3, 2017 
  • P&T Committee Meeting: May 10-11, 2017
Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • Overactive Bladder Agents: Gelnique, Myrbetriq, Oxytrol, Toviaz, Vesicare - Solicitation Cancelled
  • Ophthalmic-1 Agents: Bepreve, Emadine, Lastacaft, Pataday, Pazeo
  • Pulmonary Miscellaneous:  Esbriet, Ofev   
  • Arymo ER
  • Austedo
  • Dupixent
  • Emflaza
  • Eucrisa
  • Kisqali
  • Rhofade
  • Trulance
  • Xermelo
  • Xultophy

Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

Decision Papers

File Date
Decision Paper on Implementing ESI Commercial Reject List and Prior Authorization for all Compound Medication Prescriptions 5/8/2015

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.